$17.67
+0.27 (+1.55%)
SDGR News2 articles
AbCellera Shares Jump 9.7% Ahead of Key Phase 2 Data Release
AbCellera (ABCL) rose 9.7% after hours as investors await Phase 2 data for ABCL635, set to release Monday. The surge adds ~$205M to market cap.
Recursion Pharmaceuticals Hits New Low Amid Revenue Drop and FDA Watch
Recursion Pharmaceuticals shares fell to a 52-week low Tuesday after Q1 revenue dropped 56% year-over-year. The AI-driven biotech firm awaits FDA feedback on key trials.